Author: OurCrowd

[Anodot in PR Newswire] Automat-IT and Anodot partner to maximize AWS value

NEW YORK, Sept. 21, 2023 /PRNewswire/ — Automat-IT, a leading provider of DevOps and FinOps services, and Anodot, the augmented FinOps company, have announced a long-term strategic partnership. The partnership is focused on helping customers maximize the value of their AWS deployments. This agreement combines the expertise of both companies to deliver comprehensive services atop AWS. Read more...

Read More

[Alloy Therapeutics in Startup News] Alloy Therapeutics announces platform license agreement with Lilly

Alloy Therapeutics, a biotechnology ecosystem company dedicated to democratizing access to biologics drug discovery platforms and services, announced today a licensing agreement for its murine platforms for fully human antibody discovery with Eli Lilly and Company. The non-exclusive license provides Lilly access to the ATX-Gx™ and ATX-CLC™ mouse platforms and broad rights to use the Alloy platforms for antibody drug discovery and development under this multi-year collaboration.https://www.ourcrowd.com/startup-news/alloy-therapeutics-announces-platform-license-agreement-with-lilly Read...

Read More

[Alloy Therapeutics in Business Wire] Alloy Therapeutics announces scientific advisory board to drive roadmap of biotherapeutic discovery platform innovation

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and more. Alloy’s SAB members have been instrumental in developing Alloy’s technical roadmap as the company has developed cutting edge technologies and services across antibodies, bispecifics, TCRs and TCR mimics, genetic medicines, cell therapies, peptides and drug delivery technologies. Read...

Read More